Post-Marketing Surveillance on the Long-Term Use of Prazaxa® Capsules in Japanese Patients With Nonvalvular Atrial Fibrillation After the Availability of Idarucizumab.
Phase of Trial: Phase IV
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 25 Jul 2017 Status changed from not yet recruiting to recruiting.
- 27 Jun 2017 Planned initiation date changed from 15 Jun 2017 to 28 Jun 2017.
- 08 Jun 2017 New trial record